Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 84 entries
Sorted by: Best Match Show Resources per page
Undiagnosed Sleep Apnea Costing Billions.

Journal of the California Dental Association

[No authors listed]
PMID: 29035468
J Calif Dent Assoc. 2016 Oct 13;44(10):605.

No abstract available.

Cite
Undiagnosed Sleep Apnea Costing Billions. J Calif Dent Assoc. 2016;44(10):605
(2016). Undiagnosed Sleep Apnea Costing Billions. Journal of the California Dental Association, 44(10), 605.
"Undiagnosed Sleep Apnea Costing Billions." Journal of the California Dental Association vol. 44,10 (2016): 605.
Undiagnosed Sleep Apnea Costing Billions. J Calif Dent Assoc. 2016 Oct 13;44(10):605. PMID: 29035468.
Copy Download .nbib Format: NLM
(Expected) value-based payment: From total cost of care to net present value of care.

Healthcare (Amsterdam, Netherlands)

Counts NZ, Smith JD, Crowley DM.
PMID: 30611708
Healthc (Amst). 2019 Mar;7(1):1-3. doi: 10.1016/j.hjdsi.2018.12.005. Epub 2019 Jan 03.

No abstract available.

Cite
Counts NZ, Smith JD, Crowley DM. (Expected) value-based payment: From total cost of care to net present value of care. Healthc (Amst). 2019;7(1):1-3doi: 10.1016/j.hjdsi.2018.12.005.
Counts, N. Z., Smith, J. D., & Crowley, D. M. (2019). (Expected) value-based payment: From total cost of care to net present value of care. Healthcare (Amsterdam, Netherlands), 7(1), 1-3. https://doi.org/10.1016/j.hjdsi.2018.12.005
Counts, Nathaniel Z, et al. "(Expected) value-based payment: From total cost of care to net present value of care." Healthcare (Amsterdam, Netherlands) vol. 7,1 (2019): 1-3. doi: https://doi.org/10.1016/j.hjdsi.2018.12.005
Counts NZ, Smith JD, Crowley DM. (Expected) value-based payment: From total cost of care to net present value of care. Healthc (Amst). 2019 Mar;7(1):1-3. doi: 10.1016/j.hjdsi.2018.12.005. Epub 2019 Jan 03. PMID: 30611708; PMCID: PMC6684199.
Copy Download .nbib Format: NLM
Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis.

Orphanet journal of rare diseases

Connolly MP, Panda S, Patris J, Hazenberg BPC.
PMID: 31533773
Orphanet J Rare Dis. 2019 Sep 18;14(1):220. doi: 10.1186/s13023-019-1199-x.

BACKGROUND: A wide range of rare diseases can have fiscal impacts on government finances that extend beyond expected healthcare costs. Conditions preventing people from achieving national lifetime work averages will influence lifetime taxes paid and increase the likelihood of...

Cite
Connolly MP, Panda S, Patris J, et al. Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis. Orphanet J Rare Dis. 2019;14(1):220doi: 10.1186/s13023-019-1199-x.
Connolly, M. P., Panda, S., Patris, J., & Hazenberg, B. P. C. (2019). Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis. Orphanet journal of rare diseases, 14(1), 220. https://doi.org/10.1186/s13023-019-1199-x
Connolly, Mark P, et al. "Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis." Orphanet journal of rare diseases vol. 14,1 (2019): 220. doi: https://doi.org/10.1186/s13023-019-1199-x
Connolly MP, Panda S, Patris J, Hazenberg BPC. Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis. Orphanet J Rare Dis. 2019 Sep 18;14(1):220. doi: 10.1186/s13023-019-1199-x. PMID: 31533773; PMCID: PMC6751602.
Copy Download .nbib Format: NLM
Intersectoral Costs and Benefits of Mental and Behavioural Disorders in the Education Sector: an Exploration of Costing Methods.

The journal of mental health policy and economics

Bremmers LGM, Evers SMAA, Drost RMWA, Janssen LMM, Pokhilenko I, Paulus ATG, Norton EC, Yoon J, Cuddeback GS, Morrissey JP.
PMID: 33411675
J Ment Health Policy Econ. 2020 Sep 01;23(3):115-137.

BACKGROUND: The inclusion of indirect spillover costs and benefits that occur in non-healthcare sectors of society is necessary to make optimal societal decisions when assessing the cost effectiveness of healthcare interventions. Education costs and benefits are relevant in the...

Cite
Bremmers LGM, Evers SMAA, Drost RMWA, et al. Intersectoral Costs and Benefits of Mental and Behavioural Disorders in the Education Sector: an Exploration of Costing Methods. J Ment Health Policy Econ. 2020;23(3):115-137
Bremmers, L. G. M., Evers, S. M. A. A., Drost, R. M. W. A., Janssen, L. M. M., Pokhilenko, I., Paulus, A. T. G., Norton, E. C., Yoon, J., Cuddeback, G. S., & Morrissey, J. P. (2020). Intersectoral Costs and Benefits of Mental and Behavioural Disorders in the Education Sector: an Exploration of Costing Methods. The journal of mental health policy and economics, 23(3), 115-137.
Bremmers, Leonarda G M, et al. "Intersectoral Costs and Benefits of Mental and Behavioural Disorders in the Education Sector: an Exploration of Costing Methods." The journal of mental health policy and economics vol. 23,3 (2020): 115-137.
Bremmers LGM, Evers SMAA, Drost RMWA, Janssen LMM, Pokhilenko I, Paulus ATG, Norton EC, Yoon J, Cuddeback GS, Morrissey JP. Intersectoral Costs and Benefits of Mental and Behavioural Disorders in the Education Sector: an Exploration of Costing Methods. J Ment Health Policy Econ. 2020 Sep 01;23(3):115-137. PMID: 33411675.
Copy Download .nbib Format: NLM
The burden of physical inactivity & cardiovascular heart disease.

Comprehensive therapy

Francis K.
PMID: 9533989
Compr Ther. 1998 Feb;24(2):87-92.

Heart disease exacts a tremendous toll each year in mortality and health care expenditures. Although physical activity reduces the risk of heart disease, the population remains inactive. The importance of physical activity in risk and health care cost reduction...

Cite
Francis K. The burden of physical inactivity & cardiovascular heart disease. Compr Ther. 1998;24(2):87-92
Francis, K. (1998). The burden of physical inactivity & cardiovascular heart disease. Comprehensive therapy, 24(2), 87-92.
Francis, K. "The burden of physical inactivity & cardiovascular heart disease." Comprehensive therapy vol. 24,2 (1998): 87-92.
Francis K. The burden of physical inactivity & cardiovascular heart disease. Compr Ther. 1998 Feb;24(2):87-92. PMID: 9533989.
Copy Download .nbib Format: NLM
The current global state of movement and physical activity - the health and economic costs of the inactive phenotype.

Progress in cardiovascular diseases

Jayasinghe S, Byrne NM, Patterson KAE, Ahuja KDK, Hills AP.
PMID: 33130190
Prog Cardiovasc Dis. 2021 Jan-Feb;64:9-16. doi: 10.1016/j.pcad.2020.10.006. Epub 2020 Oct 30.

Physical inactivity is one of the major contributing factors to the global pandemic of non-communicable diseases. Unfortunately, low levels of habitual movement and physical activity (PA) are seen in an increasing proportion of populations across low- and middle-income countries...

Cite
Jayasinghe S, Byrne NM, Patterson KAE, et al. The current global state of movement and physical activity - the health and economic costs of the inactive phenotype. Prog Cardiovasc Dis. 2020;64:9-16doi: 10.1016/j.pcad.2020.10.006.
Jayasinghe, S., Byrne, N. M., Patterson, K. A. E., Ahuja, K. D. K., & Hills, A. P. (2021). The current global state of movement and physical activity - the health and economic costs of the inactive phenotype. Progress in cardiovascular diseases, 649-16. https://doi.org/10.1016/j.pcad.2020.10.006
Jayasinghe, Sisitha, et al. "The current global state of movement and physical activity - the health and economic costs of the inactive phenotype." Progress in cardiovascular diseases vol. 64 (2021): 9-16. doi: https://doi.org/10.1016/j.pcad.2020.10.006
Jayasinghe S, Byrne NM, Patterson KAE, Ahuja KDK, Hills AP. The current global state of movement and physical activity - the health and economic costs of the inactive phenotype. Prog Cardiovasc Dis. 2021 Jan-Feb;64:9-16. doi: 10.1016/j.pcad.2020.10.006. Epub 2020 Oct 30. PMID: 33130190.
Copy Download .nbib Format: NLM
Long COVID and Health Inequities: The Role of Primary Care.

The Milbank quarterly

Berger Z, Altiery DE Jesus V, Assoumou SA, Greenhalgh T.
PMID: 33783907
Milbank Q. 2021 Jun;99(2):519-541. doi: 10.1111/1468-0009.12505. Epub 2021 Mar 30.

Policy Points An estimated 700,000 people in the United States have "long COVID," that is, symptoms of COVID-19 persisting beyond three weeks. COVID-19 and its long-term sequelae are strongly influenced by social determinants such as poverty and by structural...

Cite
Berger Z, Altiery DE Jesus V, Assoumou SA, et al. Long COVID and Health Inequities: The Role of Primary Care. Milbank Q. 2021;99(2):519-541doi: 10.1111/1468-0009.12505.
Berger, Z., Altiery DE Jesus, V., Assoumou, S. A., & Greenhalgh, T. (2021). Long COVID and Health Inequities: The Role of Primary Care. The Milbank quarterly, 99(2), 519-541. https://doi.org/10.1111/1468-0009.12505
Berger, Zackary, et al. "Long COVID and Health Inequities: The Role of Primary Care." The Milbank quarterly vol. 99,2 (2021): 519-541. doi: https://doi.org/10.1111/1468-0009.12505
Berger Z, Altiery DE Jesus V, Assoumou SA, Greenhalgh T. Long COVID and Health Inequities: The Role of Primary Care. Milbank Q. 2021 Jun;99(2):519-541. doi: 10.1111/1468-0009.12505. Epub 2021 Mar 30. PMID: 33783907; PMCID: PMC8241274.
Copy Download .nbib Format: NLM
Are patients willing to incur out-of-pocket costs for pharmacogenomic testing?.

The pharmacogenomics journal

Bielinski SJ, St Sauver JL, Olson JE, Wieland ML, Vitek CR, Bell EJ, Mc Gree ME, Jacobson DJ, McCormick JB, Takahashi PY, Black JL, Caraballo PJ, Sharp RR, Beebe TJ, Weinshilboum RM, Wang L, Roger VL.
PMID: 27779246
Pharmacogenomics J. 2017 Jan;17(1):1-3. doi: 10.1038/tpj.2016.72. Epub 2016 Oct 25.

No abstract available.

Cite
Bielinski SJ, St Sauver JL, Olson JE, et al. Are patients willing to incur out-of-pocket costs for pharmacogenomic testing?. Pharmacogenomics J. 2016;17(1):1-3doi: 10.1038/tpj.2016.72.
Bielinski, S. J., St Sauver, J. L., Olson, J. E., Wieland, M. L., Vitek, C. R., Bell, E. J., Mc Gree, M. E., Jacobson, D. J., McCormick, J. B., Takahashi, P. Y., Black, J. L., Caraballo, P. J., Sharp, R. R., Beebe, T. J., Weinshilboum, R. M., Wang, L., & Roger, V. L. (2017). Are patients willing to incur out-of-pocket costs for pharmacogenomic testing?. The pharmacogenomics journal, 17(1), 1-3. https://doi.org/10.1038/tpj.2016.72
Bielinski, S J, et al. "Are patients willing to incur out-of-pocket costs for pharmacogenomic testing?." The pharmacogenomics journal vol. 17,1 (2017): 1-3. doi: https://doi.org/10.1038/tpj.2016.72
Bielinski SJ, St Sauver JL, Olson JE, Wieland ML, Vitek CR, Bell EJ, Mc Gree ME, Jacobson DJ, McCormick JB, Takahashi PY, Black JL, Caraballo PJ, Sharp RR, Beebe TJ, Weinshilboum RM, Wang L, Roger VL. Are patients willing to incur out-of-pocket costs for pharmacogenomic testing?. Pharmacogenomics J. 2017 Jan;17(1):1-3. doi: 10.1038/tpj.2016.72. Epub 2016 Oct 25. PMID: 27779246; PMCID: PMC5310981.
Copy Download .nbib Format: NLM
Methods of economic evaluation for the German statutory healthcare system.

PharmacoEconomics

Mittendorf T, Greiner W, von der Schulenburg JM.
PMID: 19354346
Pharmacoeconomics. 2009;27(3):265. doi: 10.2165/00019053-200927030-00009.

No abstract available.

Cite
Mittendorf T, Greiner W, von der Schulenburg JM. Methods of economic evaluation for the German statutory healthcare system. Pharmacoeconomics. 2009;27(3):265doi: 10.2165/00019053-200927030-00009.
Mittendorf, T., Greiner, W., & von der Schulenburg, J. M. (2009). Methods of economic evaluation for the German statutory healthcare system. PharmacoEconomics, 27(3), 265. https://doi.org/10.2165/00019053-200927030-00009
Mittendorf, Thomas, et al. "Methods of economic evaluation for the German statutory healthcare system." PharmacoEconomics vol. 27,3 (2009): 265. doi: https://doi.org/10.2165/00019053-200927030-00009
Mittendorf T, Greiner W, von der Schulenburg JM. Methods of economic evaluation for the German statutory healthcare system. Pharmacoeconomics. 2009;27(3):265. doi: 10.2165/00019053-200927030-00009. PMID: 19354346.
Copy Download .nbib Format: NLM
StatBite: National Costs for Cancer Care in 2010 in Billions of Dollars by Cancer Site.

Journal of the National Cancer Institute

[No authors listed]
PMID: 22173584
J Natl Cancer Inst. 2012 Jan 04;104(1):13. doi: 10.1093/jnci/djr534. Epub 2011 Dec 14.

No abstract available.

Cite
StatBite: National Costs for Cancer Care in 2010 in Billions of Dollars by Cancer Site. J Natl Cancer Inst. 2011;104(1):13doi: 10.1093/jnci/djr534.
(2012). StatBite: National Costs for Cancer Care in 2010 in Billions of Dollars by Cancer Site. Journal of the National Cancer Institute, 104(1), 13. https://doi.org/10.1093/jnci/djr534
"StatBite: National Costs for Cancer Care in 2010 in Billions of Dollars by Cancer Site." Journal of the National Cancer Institute vol. 104,1 (2012): 13. doi: https://doi.org/10.1093/jnci/djr534
StatBite: National Costs for Cancer Care in 2010 in Billions of Dollars by Cancer Site. J Natl Cancer Inst. 2012 Jan 04;104(1):13. doi: 10.1093/jnci/djr534. Epub 2011 Dec 14. PMID: 22173584.
Copy Download .nbib Format: NLM
Seniors will not bankrupt Canada's health system.

Lancet (London, England)

McGrail K.
PMID: 23158252
Lancet. 2012 Nov 17;380(9855):1740. doi: 10.1016/S0140-6736(12)61990-4.

No abstract available.

Cite
McGrail K. Seniors will not bankrupt Canada's health system. Lancet. 2012;380(9855):1740doi: 10.1016/S0140-6736(12)61990-4.
McGrail, K. (2012). Seniors will not bankrupt Canada's health system. Lancet (London, England), 380(9855), 1740. https://doi.org/10.1016/S0140-6736(12)61990-4
McGrail, Kimberlyn. "Seniors will not bankrupt Canada's health system." Lancet (London, England) vol. 380,9855 (2012): 1740. doi: https://doi.org/10.1016/S0140-6736(12)61990-4
McGrail K. Seniors will not bankrupt Canada's health system. Lancet. 2012 Nov 17;380(9855):1740. doi: 10.1016/S0140-6736(12)61990-4. PMID: 23158252.
Copy Download .nbib Format: NLM
AJMC panel asks: does it pay to use pathways?.

The American journal of managed care

Caffrey MK.
PMID: 25618161
Am J Manag Care. 2014 Aug;20(11):E2.

No abstract available.

Cite
Caffrey MK. AJMC panel asks: does it pay to use pathways?. Am J Manag Care. 2014;20(11):E2
Caffrey, M. K. (2014). AJMC panel asks: does it pay to use pathways?. The American journal of managed care, 20(11), E2.
Caffrey, Mary K. "AJMC panel asks: does it pay to use pathways?." The American journal of managed care vol. 20,11 (2014): E2.
Caffrey MK. AJMC panel asks: does it pay to use pathways?. Am J Manag Care. 2014 Aug;20(11):E2. PMID: 25618161.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 84 entries